Understudied populations with hepatitis C.

Area of Science:

• Hepatology
• Virology
• Clinical Trial Design

Background:

• Hepatitis C virus (HCV) infection management relies on peginterferon and ribavirin antiviral therapy.
• Current treatment guidelines are based on highly selected patient populations, excluding over half of all HCV-infected individuals.
• Limited data exist on the safety and efficacy of HCV therapy in diverse and comorbid patient groups.

Purpose of the Study:

• To highlight the limitations of current HCV treatment eligibility criteria.
• To identify patient populations excluded from existing clinical trials.
• To advocate for expanded antiviral therapy access for understudied HCV populations.

Main Methods:

• Review of existing clinical trial inclusion and exclusion criteria for HCV antiviral therapy.
• Analysis of patient characteristics that render individuals ineligible for current treatment protocols.
• Identification of barriers to treatment, including cost and side effects.

Main Results:

• Less than 50% of patients in clinical trials achieve sustained virological response (SVR).
• Numerous patient groups, including those with mild disease, advanced liver disease, comorbidities (HIV, renal disease, autoimmune disorders), children, elderly, and those with substance abuse issues, are excluded from trials.
• Cost and side effects limit treatment accessibility for patients on public assistance, in correctional facilities, or institutions.

Conclusions:

• Current HCV treatment strategies are not inclusive, leading to suboptimal outcomes and limited access.
• Significant unmet needs exist for developing and evaluating antiviral therapies in underrepresented patient populations.
• New research and therapeutic approaches are essential to broaden eligibility and improve HCV management for all patients.